Second CAR T-Cell Infusion Hits Myeloma After CELMoD Bridging
A German case report describes rapid deep response to ciltacabtagene autoleucel as a second BCMA-directed CAR T-cell therapy after mezigdomide-based ...
A German case report describes rapid deep response to ciltacabtagene autoleucel as a second BCMA-directed CAR T-cell therapy after mezigdomide-based ...
In the evolving landscape of multiple myeloma treatment, researchers are pursuing novel therapies to enhance patient outcomes, particularly for those ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine